J. F. BLAKE* ET AL. (ARRAY BIOPHARMA INC., BOULDER AND GENENTECH INC., SOUTH SAN FRANCISCO, USA)

Discovery and Preclinical Pharmacology of a Selective ATP-Competitive Akt Inhibitor (GDC-0068) for the Treatment of Human Tumors

J. Med. Chem. **2012**, *55*, 8110–8127.

Synthesis of Akt Inhibitor GDC-0068

Significance: Akt is a kinase that controls cellular processes by phosphorylating substrates involved in apoptosis, transcription, cell cycle progression and translation. GDC-0068 is an Akt inhibitor that is in clinical trials for the treatment of cancer.

SYNFACTS Contributors: Philip Kocienski
Synfacts 2013, 9(1), 0014 Published online: 17.12.2012
DOI: 10.1055/s-0032-1317718; **Reg-No.:** K09112SF

Comment: Key steps in the synthesis depicted are (1) the use of a Favorskii ring contraction in the conversion of (*R*)-pulegone (**A**) to the ester **B** and (2) the Noyori asymmetric transfer hydrogenation of ketone **J**.